Jiangsu Longhui Biotechnology Co., Ltd. (est. 2021), a subsidiary of Changzhou Xianglong Group, specializes in reference material production, quality control, value assignment,  pharmaceutical impurity profiling and small-molecule synthesis of pharmaceuticals. It holds the well-known premium reference material brand in the industry — 龙汇生物® (FDR), and is responsible for the full-process production, quality control and value assignment of Xianglong Group's reference material brand — XL Standards.

Led by returnee postdoctoral experts, the synthesis team's core members possess deep expertise in process development and total synthesis of natural products, with the capability to undertake custom synthesis of complex, high-difficulty compounds. The platform provides full-chain support for chemical synthetic drug molecules throughout the entire process—from preclinical research and clinical stages to commercial launch—covering process development and scale-up production services. Customized process development services are available for various tailored pharmaceutical impurities, pharmaceutical intermediates, and novel drug small-molecule building blocks.

Accredited with ISO 17025 (2023) and ISO 17034 (2026), the company operates an integrated system covering analysis, production, and certification. It delivers high-purity impurity standards and traceability solutions for innovative drug development, generic drug equivalence assessment, and lifecycle quality management.

Committed to customer focus, quality assurance, and innovation, Longhui offers fully regulatory-compliant products and services to global bio-pharmaceutical clients, advancing industry excellence.